SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is buzzing as industry conferences highlight promising external demand for its 18A manufacturing process and significant potential for multi-billion dollar advanced packaging deals, including a reported order from MediaTek. The community is actively discussing these developments and new AI/6G partnerships as key drivers for increasing gross margins and validating the company's strategic turnaround efforts, despite ongoing volatility.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a hot topic as the community eagerly discusses its potential integration with Elon Musk's "X money" platform, with some believing broader regulatory clarity could be a catalyst. This optimism is countered by strong bearish sentiment questioning the meme coin's fundamental utility.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

Anavex Life Sciences is trending amidst strong community speculation around an imminent European regulatory re-examination decision for its Alzheimer's drug, Blarcamesine, particularly for genetically defined patient subgroups, contrasting its oral convenience and safety profile against existing high-cost mAb treatments. This comes as investors also monitor upcoming financial updates and the strategic implications of a new board appointment for the company's European market penetration.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending due to its one-year anniversary celebration, which is fueling renewed bullish sentiment around its battle-tested passive Solana reward mechanism and ongoing token burns. The community is actively discussing its resilience and continuous development, even amidst broader market skepticism.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as a significant patent dispute settlement removes legal uncertainty and bolsters its diversified pipeline in infectious diseases and oncology, leading to community speculation about a potential short squeeze.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is a hot topic following its substantial $615 million acquisition of Covelya Group, a strategic move widely praised by the community as a game-changer for its subsea technology dominance. Despite recent share dilution, investors are largely bullish on this expansion, anticipating significant long-term growth in its dual-use defense and commercial markets.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is trending amid intense market volatility driven by escalating geopolitical tensions between the US, Israel, and Iran, leading to sharply divided community sentiment around potential "relief rallies" versus a "bloodbath" as concerns over oil supply and broader conflict persist.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin (LTC) is actively trending amid a community clash between strong bullish sentiment, driven by technical indicators and calls for a significant breakout, and growing frustration over its perceived long-term underperformance.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing extreme volatility and high trading volume, largely fueled by escalating Middle East geopolitical tensions threatening global oil supply routes and a recent significant private placement. The community is sharply divided between those anticipating further short-squeeze driven gains due to supply concerns, and others warning of a pump-and-dump, citing a recent offering at a substantially lower price point and the company's considerable debt.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is actively traded due to escalating military actions in the Middle East, including the reported death of Iran's Supreme Leader and threats to the Strait of Hormuz, sparking community debate over sustained oil supply disruptions versus efforts to stabilize global crude prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuwellis Names Carisa Schultz CFO

(RTTNews) - Nuwellis, Inc. (NUWE), a medical technology company, on Friday announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2...

<ul class="summary-bullets"><li>Nuwellis did not disclose the value of the deal that is aimed at expanding the company’s portfolio into real-time renal diagnostics.</li><li>The company said that the transaction is expected to close upon the completion of customary closing conditions.</li><li>The Minneapolis-based company also announced a $5 million private placement and warrant inducement transaction priced at-the-market.</li></ul> Shares of Nuwellis Inc. (NUWE) slumped over 16% after-hours on Thursday after the company said that it has inked an agreement to acquire Israeli medical technology company Rendiatech.Nuwellis did not disclose the value of the deal, which is aimed at expanding the company’s portfolio into real-time renal diagnostics beyond therapeutic fluid management. Rendiatech is focused on automated kidney function monitoring.The company’s current portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions. &nbsp;<h2 class="st-heading-2">Upsides Of The Transaction</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229142/26106/en/Nuwellis-Enters-into-Definitive-Agreement-to-Acquire-Rendiatech-Advancing-Its-Cardiorenal-Portfolio-Strategy.html">said </a>that the transaction is expected to close upon the completion of customary closing conditions.Upon closing, Nuwellis will gain access to Rendiatech’s Clarity technology, allowing for expansion into advanced urine-based analytics and broader kidney function assessment, the company said, adding that the establishment of new sales channels is not expected to be needed to develop Rendiatech’s technology.“By entering into this transaction, we are positioning the company to extend our capabilities beyond therapeutic fluid removal and into real-time renal monitoring, which we believe is a natural and complementary evolution of our portfolio,” CEO John Erb said.Separately, the Minneapolis-based company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229143/26106/en/Nuwellis-Announces-5-Million-Private-Placement-and-Warrant-Inducement-Transaction-Priced-At-The-Market.html">announced</a> a $5 million private placement and warrant inducement transaction priced at-the-market. The transaction is expected to close on or about Jan. 30.The company did not detail the purposes for which the proceeds will be used. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NUWE stock stayed at ‘extremely bullish’ territory while message volume stayed at ‘extremely high’ levels.A Stocktwits user said that they are bullish on the acquisition until proven otherwise.<stembedurl>https://www.stocktwits.com/Nuckle_Head/message/643368696</stembedurl><a href="https://stocktwits.com/symbol/NUWE">NUWE stock</a> has dropped over 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-reportedly-considering-merger-with-xai-ahead-of-planned-ipo/cmyilBJR41B">Elon Musk’s SpaceX Reportedly Considering Merger With xAI Ahead Of Planned IPO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Nuwellis Stock Slips Over 26% After Hours On New Acquisition, $5M Placement Announcement

The company did not disclose the value of the acquisition, which is aimed at expanding the company’s portfolio into real-time renal diagnostics.

Equity

Nuwellis, Inc. Profit Declines In Q3

(RTTNews) - Nuwellis, Inc. (NUWE) announced earnings for third quarter that Dropped, from last year...

Nuwellis shares rose in after-hours trading after the company said it was granted a new U.S. Patent for innovations in blood filtering machine design and methods that improve fluid management accuracy during ultrafiltration therapy.At the close on Tuesday, <a href="https://stocktwits.com/symbol/NUWE">Nuwellis shares</a> dropped 11.7% to $6.9, but surged 31.3% to $9.05 in after-hours trading following news of the patent grant.The patent, titled “Extracorporeal Blood Filtering Machine and Methods”, addresses a critical source of error in continuous renal replacement therapy (CRRT) by factoring in actual fluid density, rather than assuming a standard value.&nbsp;Most current systems use 1 g/mL as&nbsp;the&nbsp;default, which can lead to miscalculations in fluid balance when actual densities differ.&nbsp;The new approach allows machines to adjust calculations based on input, measurement, or derived values, improving volumetric flow tracking and patient care.The company,&nbsp;based in Minneapolis with operations in Ireland,&nbsp;markets the Aquadex SmartFlow system for ultrafiltration and is&nbsp;The patent comes on the heels of two other major corporate developments in recent months.&nbsp;In June, Nuwellis raised $4.3 million through an underwritten public offering that included common stock and warrants. The company said the proceeds would go toward working capital, general corporate purposes, and potential acquisitions.In May, Nuwellis finalized a manufacturing agreement with KDI Precision Manufacturing, transferring assembly responsibilities for its Aquadex SmartFlow console and related products.&nbsp;The partnership&nbsp;aims to expand manufacturing capacity and enhance operational efficiency, with KDI also hiring current Nuwellis assembly employees to ensure a seamless transition.On Stocktwits, retail sentiment for Nuwellis was ‘extremely bullish’ by late Tuesday, improving from the ‘bullish’ mood a day ago, amid ‘extremely high’ message volume.One user said that a back-to-back spike within 24 hours typically signals that a larger move is underway.&nbsp;<stembedurl>https://stocktwits.com/Enjoiskating1216/message/621091545</stembedurl>Another expressed confidence in a major upside, suggesting the stock could revisit the $50 mark.<stembedurl>https://stocktwits.com/BestNwest/message/621099818</stembedurl>Nuwellis’ stock has declined 86.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuwellis (NUWE) was granted a new U.S. Patent for innovations in blood filtering machine design. (Photo credit: Getty Images)

Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant

The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon following its announcement that the Centers for Medicare and Medicaid Services (CMS) will significantly hike the reimbursement levels for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the reimbursement payment rate for the Minneapolis-based company’s Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase from $413 to $1,639 per day, a major step for the company’s outpatient therapy.&nbsp; Stocktwits users celebrated the move, suggesting the stock should go much higher following the news.&nbsp; &nbsp;<stembedurl>https://stocktwits.com/xpb199/message/591140624</stembedurl><stembedurl>https://stocktwits.com/Rampageusa/message/591116254</stembedurl> &nbsp;"This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” Nestor Jaramillo, President and CEO of Nuwellis, said in a statement. “It is well understood that providing care in an outpatient setting can be a better means to manage disease and prevent costly emergency hospitalizations.”&nbsp; The move will help expand the therapy’s reach to more patients on the sub-acute or chronic disease management program.Nuvellis plans to report its <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/nuwellis-shares-surge-following-preliminary-3q-results-c5fa917d">third-quarter</a> results and host its earnings conference call on November 11. The company said recently it is expecting to report revenue of $2.4 million, in line with the year-ago period.Nuwellis shares rallied over 106% today, but the stock is down roughly 88% year-to-date. Still, the stock is seeing a major jump in activity among retail investors and traders, with today’s symbol page views on Stocktwits hitting more than 25x their average over their one-month average.For updates and corrections, email newsroom@stocktwits.com

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon| Image source: Pixabay

Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat

Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Nuwellis Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AVGO earnings on Wednesday?

Current Price	$1.46
Prev Close	$1.43
Open	$1.41
Dividend Yield	0.00%
50-Day Moving Average	$2.23
Beta	1.14
Avg. Volume	138,551.70
PE Ratio	-0.01

52-Week High	$56.28
52-Week Low	$1.40
Market Capitalization	$2.68M
EPS (Annual)	-$336.19
Price to Book	0.50
Revenue Per Employee	$230,000.00

NUWE
Nuwellis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NUWE News

NUWENuwellis Inc